Omega-6 Fatty Acids

Compound Class	Omega-6 (n-6) polyunsaturated fatty acids — first double bond at the sixth carbon from the methyl terminus
Representative Members	Linoleic acid (LA, the essential parent), gamma-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), arachidonic acid (AA)
Botanical Sources	Oenothera biennis (evening primrose), borage, blackcurrant seed; LA is ubiquitous in seed oils
Plant Part(s)	Seed (oil)
Typical Standardisation	GLA by GC; evening primrose oil typically ~8–10% GLA. Omega-6 powder formats are microencapsulated
Primary Applications	Essential fatty acid nutrition; skin-barrier and inflammatory-pathway formulation
Claim Strength (Overview)	High for essentiality of linoleic acid; Null for the flagship GLA/eczema indication (Cochrane)
Buy from Herbuno	Omega 6 Fatty Acid Powder → Evening Primrose Oil - Oenothera biennis →

Name origin: The omega-6 designation is positional chemistry, not pharmacology: it denotes a polyunsaturated fatty acid whose first double bond sits at the sixth carbon counting from the methyl (omega) end of the chain. This is a structural family, not a functional one, and its members behave very differently — a point that matters because "omega-6" is frequently discussed as though it were a single substance with a single effect, which it emphatically is not. Traditional use: Evening primrose was used by indigenous North American peoples for wounds and skin complaints, and the seed oil entered European commerce in the 20th century. But the omega-6 concept is modern nutritional biochemistry, dating to the 1929 Burr and Burr demonstration that removing fat entirely from the rodent diet produced a deficiency syndrome reversible by linoleic acid — the finding that established essential fatty acids as a category. Research trajectory: The GLA story is a clean example of a compelling mechanistic hypothesis failing at the clinical endpoint. The proposal was elegant: atopic eczema might involve a defect in delta-6-desaturase, the enzyme converting linoleic acid to GLA; supplying GLA directly would bypass the block. Evening primrose oil was developed and marketed on this rationale for decades. The Cochrane review, covering 27 studies and 1,596 participants, found it does not work. This page reports that. Commercial source: Evening primrose seed oil (GLA-bearing) and microencapsulated omega-6 powder formats.

---

Evidence for Omega-6 Fatty Acids Applications

The flagship indication for this compound class must be reported as the null result it is. A Cochrane review of oral evening primrose oil and borage oil for atopic eczema included 27 studies with 1,596 adults and children from 12 countries — 19 comparing evening primrose oil against placebo and 8 comparing borage oil — and concluded plainly that oral borage oil and evening primrose oil lack effect on eczema, with improvement similar to their respective placebos; the majority of studies were judged at low risk of bias, and the review authors concluded that further studies on these therapies would be difficult to justify (Bamford 2013 Cochrane). "Further studies would be difficult to justify" is about as definitive as evidence synthesis gets. Claim strength: Null for eczema.

The negative finding is not new and was not marginal. An early double-blind, blocked crossover trial found no significant effect on erythema, scale, excoriation, lichenification, or overall severity in 123 patients with atopic eczema of average severity, at oral evening primrose oil doses of 2 or 4 g in children and 6 or 8 g in adults — doses well above typical commercial servings (Bamford 1985). That the null result held even at 8 g/day undercuts the usual "the dose was too low" rescue. Formulators must not make eczema claims for this ingredient. Claim strength: Null.

What is firmly established is the essentiality of linoleic acid itself, and this should not be lost in the GLA disappointment. Linoleic acid is a true essential fatty acid — humans lack the desaturase enzymes to synthesise it de novo — and genuine deficiency produces a recognisable syndrome including scaly dermatitis and impaired skin-barrier function, because linoleic acid is the obligatory precursor of ceramide-bound linoleate in the stratum corneum. Essentiality, however, is not a therapeutic claim: dietary linoleic acid is abundant in ordinary seed oils, and frank deficiency is rare in populations with any dietary fat intake. Claim strength: High (essentiality); not a supplementation rationale.

The metabolic pathway explains both the hypothesis and its failure. Linoleic acid is desaturated by delta-6-desaturase to GLA, elongated to dihomo-γ-linolenic acid (DGLA), and then either converted by delta-5-desaturase to arachidonic acid — precursor of the pro-inflammatory 2-series prostaglandins and 4-series leukotrienes — or diverted to the anti-inflammatory 1-series prostaglandins. Supplying GLA was intended to push flux toward DGLA and the anti-inflammatory branch. The pathway is real; the clinical consequence, in eczema at least, is not. This is a useful cautionary case in mechanism-to-outcome inference. Claim strength: Moderate (mechanistic); Null (clinical, for eczema).

The omega-6-to-omega-3 ratio is a live and genuinely contested area, and this page will not pretend it is settled. The argument is that modern diets deliver a heavily omega-6-skewed ratio relative to ancestral intake, favouring arachidonic-acid-derived pro-inflammatory eicosanoids; the counter-argument is that linoleic acid conversion to arachidonic acid is tightly regulated and that intervention data linking high linoleic acid intake to inflammatory outcomes is weak. Formulators should present this as an open question rather than asserting either position, and should be aware that "reduce omega-6" messaging sits uneasily alongside selling an omega-6 ingredient. Claim strength: Emerging (contested).

---

Dosage & Formulator Specification

Herbuno carries Omega 6 Fatty Acid powder, evening primrose oil, and evening primrose extract in powder, water-soluble, and oil-soluble formats. Buyers should be clear about which member of the class their formulation requires: linoleic acid and GLA are chemically and functionally distinct, and an "omega-6" designation alone does not specify a product.

Dosing guidance must be honest about what the evidence supports. The eczema trials that failed used evening primrose oil at 2–8 g/day, so a formulator cannot argue the null result away on dose grounds. There is no established therapeutic dose for GLA supported by robust human evidence for the indications on which this ingredient is conventionally sold. For linoleic acid, adequate-intake nutritional reference values exist and are readily met by ordinary dietary fat intake, meaning a supplementation rationale is weak in populations without documented deficiency. Formulators should scope claims to essential-fatty-acid nutrition rather than therapeutic effect.

Analytical verification should specify the full fatty acid profile by gas chromatography — not merely a total omega-6 figure — with linoleic acid and GLA quantified separately, since these are functionally distinct. Peroxide value and anisidine value are essential for any polyunsaturated oil, as omega-6 fatty acids are highly oxidation-prone and rancidity is both a quality and a safety concern; oxidised lipid is not a benign impurity. For microencapsulated powder formats, the carrier system, oil load, and oxidative stability across shelf life should be documented rather than assumed.

Evening primrose and borage oils are generally well tolerated, with the Cochrane review noting mild, transient, mainly gastrointestinal adverse effects comparable to placebo. Two cautions warrant statement. Evening primrose oil is listed as a known cause of increased bleeding in people taking warfarin, and concurrent use with anticoagulants therefore requires caution and medical supervision — the Cochrane authors specifically noted that the included studies did not evaluate bleeding effects. Second, borage oil may contain hepatotoxic pyrrolizidine alkaloids unless specifically certified PA-free, and this certification should be required rather than assumed for any borage-derived material.

---

Frequently Asked Questions — Omega-6 Fatty Acids

Does evening primrose oil help eczema?
No. A Cochrane review of 27 studies and 1,596 participants found that oral evening primrose oil and borage oil lack effect on eczema, with improvement similar to placebo — and most included studies were at low risk of bias. The authors concluded that further studies would be difficult to justify. Eczema claims for this ingredient are not supportable.

Could the trials have used too low a dose?
That rescue does not work here. An early double-blind crossover trial in 123 patients used evening primrose oil at 2-4 g in children and 6-8 g in adults — well above typical commercial servings — and still found no significant effect on erythema, scaling, excoriation, lichenification, or overall severity.

Is linoleic acid still essential?
Yes, and this should not be lost in the GLA disappointment. Humans cannot synthesise linoleic acid, and genuine deficiency produces scaly dermatitis and impaired skin-barrier function. But essentiality is not a therapeutic claim — linoleic acid is abundant in ordinary seed oils and frank deficiency is rare in anyone with dietary fat intake.

Is the omega-6 to omega-3 ratio a real concern?
It is genuinely contested and we will not pretend otherwise. One argument holds that modern diets are omega-6-skewed, favouring pro-inflammatory eicosanoids. The counter is that linoleic acid conversion to arachidonic acid is tightly regulated and the intervention data is weak. Formulators should treat it as an open question rather than asserting either side.

Related compounds: Linoleic Acid, Alpha-Linolenic Acid, EPA/DHA Omega-3, Saw Palmetto Fatty Acids

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery